Issue #163

Cannabis Rescheduling: Two Picks Under $3

The cannabis sector is preparing for its most significant regulatory shift in decades as the United States moves toward federal rescheduling. While the headlines focus on immediate tax relief under Section 280E for domestic operators, the smartest way to play this transition isn't necessarily by chasing high-debt, high-valuation US multi-state operators. Instead, the real opportunity is quietly emerging in capital-efficient, fundamentally sound businesses that are built to thrive as global markets open up. Both of today's selections trade for under $3, offering highly asymmetric entry points into this regulatory wave.

While these Canadian-headquartered operators won't see an immediate, direct reduction in their own tax bills from US 280E relief, the macro shift validates their business models, clears the path for international expansion, and triggers a massive capital reallocation across the entire sector.

👉 One company is a dominant, operationally sound retailer that has built a highly loyal discount club model, proving that brick-and-mortar cannabis can be highly resilient even in hyper-competitive markets.

👉 The other is a well-capitalized, asset-light global operator focused on intellectual property, wellness, and pharmaceutical-grade cannabinoid science, backed by a massive cash cushion.

👉 Both names trade under $3, avoid the extreme balance sheet risks of their peers, and are uniquely positioned to capture the massive indirect tailwinds of US federal rescheduling.

In this edition, we break down why High Tide Inc. (HITI) and Cronos Group Inc. (CRON) represent the smartest, most resilient ways to position your portfolio for the era of Cannabis Federal Rescheduling & 280E Relief.

Investors are watching this fast-growing tech company

No, it's not Nvidia... It's Mode Mobile, 2023's fastest-growing software company according to Deloitte.

Their EarnPhone has helped users earn and save over $1B, driving $115M+ in revenue and an eye-popping 32,481% revenue growth. And having secured partnerships with Walmart and Best Buy, Mode's not stopping there...

Like Uber turned vehicles into income-generating assets, Mode is turning smartphones into an easy passive income source. The difference is, investors like you still have a chance to invest in Mode's pre-IPO offering at $0.52/share.

They've just been granted the stock ticker $MODE by the Nasdaq and over 59,000 investors participated in their previous rounds.

$71M+ already invested – claim your stake at $0.52/share and earn up to a 20% bonus

Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile's Regulation A Offering.

---

High Tide Inc. (NASDAQ: HITI) is a leading, retail-forward cannabis enterprise that has quietly established itself as one of the most operationally sound and strategically positioned players in the global cannabis landscape. Headquartered in Canada, the company operates an innovative discount club retail model under the Canna Cabana banner, alongside a robust international e-commerce ecosystem for consumption accessories and a growing medical cannabis footprint in Europe. Unlike many of its peers in the Canadian and international markets that have struggled with chronic unprofitability and structural oversupply, High Tide has carved out a highly resilient niche by focusing on retail execution, customer loyalty, and capital efficiency. As the global regulatory environment shifts—particularly with impending rescheduling decisions in the United States and liberalization efforts in Europe—High Tide stands out as a unique vehicle for investors seeking exposure to the cannabis sector's secular growth without the extreme balance sheet risks that plague many of its competitors.

Business Model and Revenue Streams 📦

At the core of High Tide's commercial success is its highly disruptive discount club retail business model, operating primarily through its Canna Cabana brick-and-mortar storefronts. This model functions similarly to warehouse club concepts like Costco, but tailored specifically for the cannabis consumer. By offering high-quality cannabis products and consumption accessories at deeply discounted prices to its loyalty members, High Tide has successfully built a massive and highly recurring customer base. This strategy has allowed the company to consistently capture market share from both independent "mom-and-pop" dispensaries and larger, more traditional retail competitors. The discount club model relies on high inventory turnover and volume to offset lower gross margins, a strategy that has proven incredibly effective in the highly competitive and price-sensitive Canadian retail market.

Beyond its physical retail footprint, High Tide has diversified its revenue streams to mitigate geographic and regulatory risks. The company operates a portfolio of established e-commerce platforms specializing in consumption accessories, which serve a global customer base, particularly in the United States and Europe. This digital ecosystem not only generates high-margin auxiliary revenue but also provides High Tide with invaluable consumer data and a pre-existing brand presence in markets where recreational cannabis is not yet fully legalized. Furthermore, the company has expanded into the European medical cannabis market through its subsidiary, Remexian Pharma GmbH, in Germany. This multi-pronged revenue structure—spanning brick-and-mortar discount retail, global e-commerce, and international medical cannabis distribution—creates a robust operational foundation that is far more resilient than a single-market retail business.

Macroeconomic policies and regulatory shifts exert a profound impact on High Tide's operational trajectory. In Canada, the retail cannabis sector is heavily taxed and strictly regulated, which has historically compressed margins across the industry. However, High Tide's scale and efficient discount model have allowed it to navigate these headwinds far better than its peers. On the international front, macroeconomic factors such as interest rates and capital availability are critical. The cannabis sector has faced a prolonged capital drought, making traditional debt and equity financing exceptionally expensive or dilutive. High Tide's ability to secure favorable financing terms, even in a high-rate environment, is a key competitive advantage.

Additionally, the broader regulatory landscape is undergoing historic changes. In the United States, the potential reclassification of cannabis by the Drug Enforcement Administration (DEA) to Schedule III is a highly anticipated catalyst. While High Tide does not currently operate direct plant-touching retail assets in the U.S. due to federal prohibition, a federal rescheduling would dramatically lower the cost of capital, reduce tax burdens under Section 280E for U.S. operators, and ultimately pave the way for High Tide to export its highly successful Canna Cabana retail model south of the border. Meanwhile, in Europe, Germany's recent legislative reforms regarding medical cannabis have unlocked a massive growth engine, allowing High Tide to rapidly scale its medical distribution operations in the continent's largest economy.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

• Revenue: $178,609,929 for the latest reported quarter ended January 31, 2026, representing a robust year-over-year growth rate of 25.37% compared to the same period in the prior year.
• Net Profit: $1,206,897 for the quarter ended January 31, 2026, marking a significant milestone as the company transitions into consistent positive net income.
• Diluted Earnings Per Share (EPS): $0.0138 for the quarter ended January 31, 2026, demonstrating clear earnings power at the individual share level.
• Revenue Growth Trend: Sustained double-digit top-line expansion driven by organic growth in existing stores, new store openings, and international medical cannabis distribution.

Strategic Initiatives and Mergers: 🤝

High Tide has continued to aggressively expand its physical retail footprint in Canada while simultaneously executing on high-impact international initiatives. In mid-2026, the company announced the opening of several new Canna Cabana locations in key metropolitan areas, including Toronto, Welland, and Calgary. These new store openings are part of High Tide's ongoing strategy to deepen its market penetration in high-traffic urban centers and leverage its established brand equity. The rapid rollout of physical stores is supported by the continuous growth of its Cabana Club loyalty program, which remains a key driver of customer retention and high average basket sizes.

On the international stage, High Tide's German subsidiary, Remexian Pharma GmbH, achieved a record-breaking milestone by distributing 7.6 tonnes of medical cannabis during the quarter. This achievement accelerates High Tide's leadership in the rapidly expanding German medical market, which has experienced a surge in demand following recent regulatory liberalizations. By securing a dominant position in the German wholesale medical sector, High Tide is well-positioned to capitalize on further European policy reforms.

Perhaps the most significant corporate development of recent months occurred on May 5, 2026, when High Tide executed a term sheet for $40 million in credit facilities with a Big 5 Canadian Chartered Bank. Securing a credit facility of this magnitude from a premier, traditional financial institution is a massive vote of confidence in High Tide's financial health and business model. This non-dilutive financing package provides the company with a highly competitive cost of capital, allowing it to fund its growth initiatives, execute strategic acquisitions, and manage its balance sheet without relying on highly dilutive equity raises. Additionally, on May 11, 2026, the company reported multiple stock purchases by key corporate insiders, demonstrating strong management alignment with public shareholders and a shared belief in the company's long-term value proposition.

Profitability and Fair Value 🎯

High Tide's financial trajectory highlights a clear and accelerating path toward sustained profitability, distinguishing it from the vast majority of its cannabis peers. While the company's trailing twelve months (TTM) P/E ratio stands at -6.04—reflecting historical net losses and the heavy capital expenditure required to build out its retail infrastructure—the latest reported quarter ended January 31, 2026, delivered a positive net income of $1.2 million and an EPS of $0.0138. This positive inflection point indicates that High Tide's discount club model has achieved the critical mass and operational leverage necessary to generate real bottom-line profits. As the company continues to scale its high-margin recurring revenue streams, such as its Cabana Elite paid membership tier and international digital sales, net margins are expected to expand further.

From a valuation perspective, High Tide appears remarkably undervalued relative to its growth profile and operational execution. The stock currently trades at a trailing twelve months Price-to-Sales (P/S) ratio of approximately 0.45. For a company growing its top-line revenue at over 25% year-over-year and demonstrating positive quarterly net income, a P/S ratio below 0.5 is exceptionally low. This depressed valuation is largely a function of the broader "cannabis discount" applied by the market, as regulatory gridlock in the United States and historical capital destruction by other Canadian operators have kept institutional capital on the sidelines. (Note: Due to the negative TTM net earnings and negative TTM EBITDA, standard trailing P/E, PEG, and EV/EBITDA metrics are omitted from this value comparison to maintain strict financial discipline).

When compared to its direct competitors, High Tide's valuation looks highly favorable. The company is actively taking market share, expanding its footprint, and has secured a non-dilutive $40 million credit facility from a major Canadian bank—all while trading at a fraction of its annual revenue. As the company continues to post positive net income quarters and the regulatory environment eases, a re-rating toward a more normalized retail valuation multiple appears highly plausible.

Analyst Estimates and Ratings 📊

Consensus Rating: Buy

Price Target: Highly favorable relative to current trading levels, supported by recent positive revisions.

High Tide currently enjoys strong backing from the analyst community, reflecting its status as a preferred pick within the cannabis and pharmaceutical retail sectors. The current six-month consensus rating stands at a unanimous Buy, with no Hold or Sell ratings reported. This positive sentiment is reinforced by recent street action, where leading analysts have reiterated their Buy ratings and revamped their expectations ahead of upcoming quarterly earnings releases.

Wall Street forecasters have increasingly recognized that High Tide's discount club model is structurally superior to traditional cannabis retail formats, allowing it to maintain high sales volumes and capture market share even during periods of economic uncertainty. The recent insider buying activity and the landmark $40 million credit facility with a Big 5 Canadian bank have further validated the bullish thesis, prompting analysts to view the stock as a highly attractive, low-risk entry point into the cannabis space at its current share price of approximately $2.29.

Investor-Focused Takeaway: Is HITI Right for Your Portfolio?

What to Watch in the Near Term: 📈

• Q2 2026 Earnings Release (Catalyst on August 14, 2026): Investors should closely monitor whether High Tide can sustain the positive net income and EPS growth established in the quarter ended January 31, 2026, and assess the impact of newly opened Canna Cabana locations on overall margins.
• DEA Schedule III Reclassification Update (Catalyst on August 15, 2026): This regulatory decision in the United States represents a massive macro catalyst that could spark a sector-wide re-rating and accelerate High Tide's long-term U.S. retail expansion strategy.
• Potential Debt Refinancing or Dilutive Offering (Catalyst on September 30, 2026): While the newly secured $40 million bank credit facility significantly reduces liquidity risks, investors should watch how the company manages its existing debt obligations and whether any minor dilutive equity actions are taken to accelerate growth.
• German Market Scaling: Watch for continued volume growth in medical cannabis distribution through Remexian Pharma GmbH as Germany's liberalized market matures.

Recommendation:

High Tide Inc. presents a highly compelling opportunity for growth-oriented investors who want exposure to the cannabis sector but demand fundamental financial discipline. Unlike speculative, highly leveraged multi-state operators or unprofitable Canadian producers, High Tide has built a sustainable, high-growth retail engine that is already generating positive quarterly net income. Trading at a highly depressed TTM P/S ratio of just 0.45, the stock is priced like a struggling retailer despite growing at a 25% year-over-year clip and securing the backing of a major Canadian chartered bank. While regulatory risks and the potential for near-term price action volatility remain inherent to the cannabis sector, High Tide's robust balance sheet, insider alignment, and proven discount club model make it one of the safest and most attractive ways to play the global cannabis rescheduling theme. For investors with a medium-to-long-term horizon, HITI represents a high-quality, asymmetric bet on the institutionalization of the cannabis industry.

Dow Drops 540 Points, Oil Soars

Middle East conflict sends markets plunging, oil jumping 8.5%. Investors flee to gold, but Marc's found a better crisis hedge - monthly income from oil, not stocks.

Full details to learn more here

---

Cronos Group Inc. (NASDAQ: CRON) is a pioneering global cannabis operator that has strategically positioned itself at the intersection of consumer packaged goods, wellness, and pharmaceutical-grade cannabinoid science. Operating within the healthcare sector and classified under the GICS Pharmaceuticals sub-industry, Cronos focuses on building an IP-rich, asset-light portfolio of brands rather than over-investing in capital-intensive cultivation infrastructure. Best known for its highly successful Canadian adult-use brand Spinach, the company has successfully expanded its footprint across multiple continents, positioning itself as a prime beneficiary of both domestic market stabilization and international regulatory shifts. With a market capitalization of approximately $1.0 billion and a share price trading in an accessible under-$5 band at around $2.74, Cronos represents a unique, cash-rich vehicle for investors looking to gain exposure to the rapidly evolving global cannabis landscape.

Business Model and Revenue Streams 📦

Cronos Group operates a highly differentiated business model within the cannabis sector. While many of its early Canadian peers rushed to construct massive, expensive cultivation facilities—which subsequently led to severe oversupply, price compression, and painful asset write-downs—Cronos adopted a disciplined, brand-first, asset-light strategy. The company focuses its capital on intellectual property, product formulation, brand equity, and international distribution, while outsourcing a significant portion of its raw biomass sourcing to specialized partners. This approach allows Cronos to maintain high-quality standards and rapid product innovation cycles without being weighed down by the heavy fixed costs of agricultural operations.

The company's revenue streams are broadly divided into two primary categories: domestic adult-use (recreational) sales in Canada and international medical cannabis sales. In Canada, Cronos has established a dominant market presence through its flagship brand, Spinach. The brand spans multiple high-margin product categories, including flower, pre-rolls, gummies, and vapes. Spinach has achieved remarkable consumer loyalty, particularly in the highly competitive vape category, where its focus on bold flavor profiles, reliable hardware, and consistent cannabinoid delivery has resonated deeply with adult consumers. Internationally, Cronos exports medical cannabis to established and emerging markets, including Israel, Germany, and Australia. These international markets typically offer higher average selling prices and superior margin profiles compared to the highly taxed and price-compressed Canadian recreational market, making international expansion a critical engine for the company's top-line growth.

Macroeconomic policies and regulatory frameworks play an oversized role in shaping Cronos Group's financial trajectory. Domestically, the Canadian market remains heavily burdened by high excise taxes, strict packaging regulations, and marketing limitations, which compress operating margins for all licensed producers. However, the macroeconomic picture is shifting favorably on the international stage. In Europe, Germany's recent de-scheduling and partial legalization of cannabis have dramatically expanded the addressable medical market, simplifying the prescription process for doctors and driving patient acquisition.

Even more significant is the pending regulatory catalyst in the United States. The US Drug Enforcement Administration (DEA) is currently moving forward with a proposal to transition cannabis from Schedule I to Schedule III under the Controlled Substances Act. This federal rescheduling, which has a major policy update catalyst highlighted on October 15, 2026, represents a structural paradigm shift. Under Schedule I, cannabis businesses are subject to Section 280E of the Internal Revenue Code, which prohibits companies from deducting ordinary business expenses from their gross income, resulting in effective tax rates that can exceed 70% to 80%. A move to Schedule III would eliminate the burden of Section 280E, instantly transforming the cash flow dynamics of the entire industry and paving the way for uplisting to major US exchanges and broader institutional ownership. While Cronos does not currently operate direct plant-touching businesses in the US due to federal laws, its massive cash reserve—originally secured via a multi-billion dollar strategic investment from tobacco giant Altria Group—gives it the dry powder necessary to aggressively enter the US market the moment federal barriers fall.

Recent Performance and Corporate Developments 📈

Q1 2026 Financial Highlights: 💰

* Revenue: For the latest reported quarter ended March 31, 2026, Cronos Group delivered revenue of $44,583,763. This represents a robust year-over-year growth rate of 38.19% compared to the same period in the prior year, driven primarily by surging international medical sales and continued market share gains in Canada. (Note: Some company press releases cited net revenue of $45.2 million, representing a 40% year-over-year increase, highlighting outperformance against internal targets).

* Net Profit/Loss: Cronos reported a net income of $13,561,511 for the quarter ended March 31, 2026, translating to an EPS of $0.0357.

* Operating Performance and Margins: Despite the positive net income on the bottom line, Cronos posted a modest operating loss of approximately $1.8 million during the quarter. The transition from an operating loss to a substantial net profit of $13.56 million was primarily driven by non-operating items, most notably the interest income generated from the company's substantial cash and short-term investment holdings, which continue to yield high returns in the current elevated interest rate environment.

* Segment and Brand Growth: The company achieved record net revenue and gross profit in the quarter, fueled by its ninth consecutive quarter of holding the number one market share position in the Canadian vape category under the Spinach brand.

Strategic Initiatives and Mergers: 🤝

Cronos Group has remained highly active on the corporate development front, leveraging its fortress balance sheet to execute targeted mergers, acquisitions, and product launches. A key highlight in recent months is the company's strategic move to acquire CanAdelaar, an established distributor in the European medical cannabis space. This acquisition is designed to accelerate Cronos's distribution capabilities in Germany and other European markets, allowing the company to capture a larger share of the margin chain by controlling distribution rather than relying solely on third-party wholesalers.

On the product innovation front, Cronos continues to push the envelope in the Canadian market. In May 2026, the company officially expanded its pre-roll portfolio with the launch of Spinach STIX, an innovative line of infused pre-rolls designed to appeal to experienced consumers seeking higher potency and enhanced flavor profiles. This launch builds upon the sustained success of the Spinach brand, which has solidified its position as the premier vape brand in Canada. By continuously refreshing its product pipeline with high-margin formats like infused pre-rolls and advanced vape hardware, Cronos is successfully defending its market share against low-cost competitors while improving its overall product mix.

Profitability and Fair Value 🎯

Analyzing Cronos Group's path to profitability requires a careful look at its unique capital structure. While the company achieved a positive net income of $13,561,511 in its latest reported quarter ended March 31, 2026, its trailing twelve-month (TTM) P/E ratio stands at -508.11. This negative TTM P/E ratio reflects the fact that on a full-year basis, the company is still working through historical net losses and the ongoing costs of scaling its international business. However, the positive net income in the most recent quarter is a highly encouraging sign that the company is closing the gap toward sustainable, operations-driven profitability.

From a valuation standpoint, Cronos trades at a trailing twelve-month Price-to-Sales (P/S) ratio of approximately 6.34 to 6.47. While a P/S ratio in this range represents a premium compared to some of its deeply distressed Canadian peers, this premium is well-justified by the company's clean balance sheet and strong top-line growth of over 38% year-over-year. Many cannabis operators are currently burdened by toxic debt and dilutive financing structures; in contrast, Cronos holds a massive, debt-free cash pile that provides an unparalleled safety cushion.

This financial strength is further illuminated by the company's trailing twelve-month EV/EBITDA ratio, which stands at an incredibly low 3.96. Because Enterprise Value (EV) subtracts net cash from market capitalization, Cronos's low EV/EBITDA ratio highlights just how heavily the market is discounting the company's operating business relative to its cash reserves. Essentially, when you buy Cronos at its current market cap of ~$1.0 billion, a massive portion of that valuation is backed directly by cash on hand, meaning investors are acquiring the core cannabis business—including the market-leading Spinach brand and its expanding international distribution network—at an incredibly depressed valuation. For value-conscious growth investors, this provides an exceptional margin of safety.

Analyst Estimates and Ratings 📊

Consensus Rating: Outperform

Price Target: While the specific numerical consensus price target is not detailed in the current research packet, the qualitative sentiment from the street is overwhelmingly positive. The latest street action designates Cronos Group as an "Outperform."

This newsletter actively screens for stocks experiencing strong buy-side momentum and positive analyst sentiment. On May 13, 2026, following the company's stellar Q1 earnings release, analysts upgraded Cronos Group to a "Buy," citing "Excellent M&A And Favorable Valuation." Wall Street is increasingly recognizing that Cronos's combination of high double-digit revenue growth, a dominant market share in Canada, an expanding international footprint, and a debt-free balance sheet makes it one of the safest and most compelling vehicles for riding the upcoming global cannabis legalization wave. With an average daily trading volume of 766,619 shares, the stock offers ample liquidity for retail and institutional investors alike, without the extreme illiquidity risks that plague smaller micro-cap operators in the space.

Investor-Focused Takeaway: Is CRON Right for Your Portfolio?

What to Watch in the Near Term: 📈

* Q2 2026 Earnings Release (August 9, 2026): Investors should closely monitor this upcoming catalyst to see if Cronos can maintain its ~38% year-over-year revenue growth trajectory and continue narrowing its operating losses.

* US Federal Rescheduling & Policy Update (October 15, 2026): This is the single most important industry-wide catalyst of the year. Any definitive progress on moving cannabis to Schedule III will likely trigger a massive rerating of the entire sector, with Cronos poised to lead the charge due to its cash-rich position.

* Integration of CanAdelaar: Watch for updates on how quickly the CanAdelaar acquisition is integrated and whether it successfully accelerates Cronos's high-margin medical sales growth in Germany and broader Europe.

* Canadian Market Share Defense: Monitor whether the newly launched Spinach STIX pre-rolls and updated vape hardware can help Cronos defend its number one market share position in Canada against aggressive, price-cutting competitors.

Recommendation:

Cronos Group Inc. (NASDAQ: CRON) presents a highly compelling risk-reward proposition for forward-looking investors. Unlike many of its peers that are struggling to survive under the weight of high debt, punitive taxes, and dilutive capital raises, Cronos is armed with a fortress balance sheet and a massive cash reserve that protects it from high interest rates. The company's asset-light strategy is clearly paying off, as evidenced by its outstanding 38.19% year-over-year revenue growth in the latest reported quarter and its long-standing dominance in the Canadian vape market.

However, investors must remain mindful of the inherent volatility of the cannabis sector. While the company's latest quarter delivered a positive net income of $13.56 million, its operating business still recorded a minor loss of $1.8 million, meaning the bottom-line profit remains reliant on interest income from its cash reserves. Additionally, much of the long-term investment thesis hinges on regulatory progress in the US and Europe. For investors seeking a high-growth, cash-backed, and fundamentally sound vehicle to play the global cannabis and rescheduling theme, Cronos Group is a standout "Buy" on market pullbacks, offering a rare combination of safety, growth, and explosive regulatory upside.

STOCK WARNING: Move Your Money This Monday

20-year trading veteran Tim Bohen just identified a dirt-cheap stock that could soar 100% or MORE this coming Monday...

Click here for the full details on this urgent opportunity now.

---

Final Take: Operational Execution and Balance Sheet Strength in the New Cannabis Era

The cannabis sector is rapidly transitioning from a period of unbridled speculation to one defined by operational maturity and capital discipline. As regulatory milestones—including U.S. rescheduling efforts and European liberalization—move closer to reality, the market is shifting its focus. The winners of this next cycle will not be the companies that spent recklessly on massive cultivation footprints, but those that have built resilient, capital-efficient business models.

That's where High Tide (HITI) and Cronos Group (CRON) stand apart.

🛒 High Tide Inc. (HITI) — The Capital-Efficient Cannabis Retail Powerhouse

✔ Highly resilient discount club retail model under the Canna Cabana banner, driving strong customer loyalty

✔ Diversified revenue streams through a robust international e-commerce ecosystem for consumption accessories

✔ Exceptional operational discipline and capital efficiency, carving out a resilient niche in a highly competitive landscape

➤ Best for: Investors looking for a proven, retail-forward operator with a highly loyal customer base and exposure to international market liberalization.

🌿 Cronos Group Inc. (CRON) — The Asset-Light, IP-Rich Global Innovator

✔ Highly liquid, cash-rich balance sheet that provides unparalleled downside protection and strategic flexibility

✔ Asset-light, IP-focused model that prioritizes high-margin consumer brands over capital-intensive cultivation infrastructure

✔ Established global footprint with a strong adult-use brand portfolio, well-positioned to benefit from shifting international regulations

➤ Best for: Value-conscious investors seeking a cash-backed, low-overhead cannabis play with significant long-term optionality in global markets.

Investor Insight

🧩 Want a highly efficient, resilient retail operator with a dominant loyalty program? → HITI

⚙️ Want a fortress balance sheet and an asset-light brand portfolio with global regulatory optionality? → CRON

Bottom Line:

The next phase of the cannabis market belongs to operators who prioritize execution over expansion. High Tide has built a highly defensive, capital-efficient retail engine that continues to capture market share, while Cronos Group offers a pristine, cash-rich balance sheet and a scalable brand portfolio primed for global regulatory tailwinds.

As the industry transitions toward institutional legitimacy, HITI and CRON represent two of the most disciplined, strategically sound ways to navigate the space.

Not investment advice. Do your own research.